Low-Dose Intravenous Recombinant Tissue-Type Plasminogen Activator Therapy for Patients With Stroke Outside European Indications | Zendy

Masatoshi Koga | Zendy; Yoshiaki Shiokawa | Zendy; Jyoji Nakagawara | Zendy; Eisuke Furui | Zendy; Kazumi Kimura | Zendy; Hiroshi Yamagami | Zendy; Yasushi Okada | Zendy; Yasuhiro Hasegawa | Zendy; Kazuomi Kario | Zendy; Satoshi Okuda | Zendy; Kaoru Endô | Zendy; Tetsuya Miyagi | Zendy; Masato Osaki | Zendy; Kazuo Minematsu | Zendy; Ḱazunori Toyoda | Zendy

Open Access

Low-Dose Intravenous Recombinant Tissue-Type Plasminogen Activator Therapy for Patients With Stroke Outside European Indications

Author(s) -

Masatoshi Koga,

Yoshiaki Shiokawa,

Jyoji Nakagawara,

Eisuke Furui,

Kazumi Kimura,

Hiroshi Yamagami,

Yasushi Okada,

Yasuhiro Hasegawa,

Kazuomi Kario,

Satoshi Okuda,

Kaoru Endô,

Tetsuya Miyagi,

Masato Osaki,

Kazuo Minematsu,

Ḱazunori Toyoda

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.631176

Subject(s) - medicine , intracerebral hemorrhage , plasminogen activator , recombinant dna , stroke (engine) , tissue plasminogen activator , surgery , t plasminogen activator , gastroenterology , subarachnoid hemorrhage , mechanical engineering , biochemistry , chemistry , engineering , gene

The purpose of this study was to determine the safety and efficacy of intravenous recombinant tissue-type plasminogen activator (0.6 mg/kg alteplase) within 3 hours of stroke onset in Japanese patients outside the indications in the European license.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research